The Specialty Pharmacy Coordination Problem: Why Patients Still Get Lost Between Prescription and Treatment

By Todd Eury | Founder & Editor-in-Chief, Pharmacy Podcast Network
A physician prescribes a potentially life-changing medication. The patient leaves the appointment hopeful. The prescription is sent, and everyone assumes treatment is underway.
Except sometimes, it isn't.
Somewhere between the prescriber, insurance company, manufacturer, and specialty pharmacy, the process stalls. A prior authorization sits unresolved. Financial assistance hasn't been arranged. The prescription gets transferred. Nobody knows who owns the next step.
And the patient waits.
This is one of specialty pharmacy's biggest problems: We have extraordinary medications, but getting them into patients' hands remains unnecessarily complicated.
The Numbers Tell a Troubling Story
Recent research demonstrates just how significant this problem has become.
A March 2026 study in the Journal of Managed Care & Specialty Pharmacy found that 9.9% of prescriptions directed to external specialty pharmacies were never filled, compared with 6.5% at the health system specialty pharmacy studied. Patients using external pharmacies also experienced longer turnaround times.
An April 2026 JAMA Health Forum study examined more than 205,000 branded medication dispensing transactions initially rejected for prior authorization. Only 35% were processed the same day. The remaining 65% required a median of six days to process. Although this broader study wasn't limited to specialty drugs, it illustrates the operational friction surrounding prescription access.
The problem doesn't necessarily end when insurance approves treatment.
An October 2026 Journal of Clinical Oncology study involving 12,134 patients prescribed specialty oral anticancer medications found that, within 90 days, only 54.5% of Medicare patients and 45.5% of commercially insured patients had both insurer approval and a filled prescription.
And according to IQVIA's November 2026 analysis, abandonment among commercially insured patients with approved oncology prescriptions reached 37% in rural areas versus 26% in metropolitan communities.
These are different patient populations and study designs, but the broader message is unmistakable: A prescription written is not necessarily a treatment started.
Meeting Chris Corsi at NASP 2026
During the National Association of Specialty Pharmacy's inSPire 2026 conference, I had the opportunity to meet Chris Corsi, CEO of CassianRx.

What stood out wasn't simply another technology executive talking about artificial intelligence. It was Chris's genuine passion for specialty pharmacy and his commitment to improving the operational processes that determine whether patients actually receive treatment.
His work reflects a straightforward mission: make specialty pharmacy operations more connected, efficient, and responsive to patients.
Chris recognizes something our industry occasionally overlooks. Technology is valuable only when it helps the people responsible for delivering care.
CassianRx Introduces ONE Journey
On April 22, 2026, CassianRx announced ONE Journey, short for Optimized Network for Engagement. The platform is designed to connect providers, specialty pharmacies, pharmaceutical manufacturers, payers, and patients through a coordinated workflow operating alongside existing systems.
"Rather than expecting pharmacists and care coordinators to chase information across disconnected platforms, ONE Journey aims to provide shared visibility into each patient's treatment journey." --Chris Corsi
Its announced capabilities include automated intake and fulfillment workflows, escalation tracking, patient communications, and AI-supported identification of next steps.
Imagine a prescription encountering an insurance restriction. Instead of disappearing into another administrative queue, the appropriate team receives an actionable alert and can track the case toward resolution.
That's the kind of coordination specialty pharmacy needs.
Promising Technology, but What Does the Evidence Show?
CassianRx reports patient engagement rates of 80–90% across enrolled programs, along with internal improvements in turnaround time, prescription conversion, adherence, and persistence. Those results are encouraging, but an important distinction matters.
These figures are company-reported performance claims, not independently validated evidence that ONE Journey improves treatment initiation or clinical outcomes.
The public announcement does not provide sufficient methodological detail, comparison groups, or standardized definitions to independently evaluate those improvements.
To demonstrate measurable value, I'd want to see several performance indicators tracked before and after implementation:
Time to therapy: Median days from prescription to first fill and confirmed first dose.
Prescription conversion: Percentage of new prescriptions successfully reaching patients within 7, 14, and 30 days.
Abandonment: Percentage never filled, with documented reasons including cost, coverage denials, and transfers.
Patient engagement: Successful contact rates, responsiveness, and unresolved support needs.
Treatment continuity: Persistence at 90 and 180 days, alongside pharmacist administrative workload.
Ideally, those measurements would be compared against similar patients and workflows not using the platform, with results broken down by therapy and payer. Technology cannot independently eliminate high medication costs, restrictive insurance policies, or clinical barriers. But better coordination could help pharmacy teams identify those problems earlier and respond more effectively.
The Real Opportunity: Connecting the Entire Journey
Specialty pharmacy doesn't necessarily need another dashboard. It needs reliable connections between the people making decisions that affect patient care. That's why the conversation around CassianRx and ONE Journey is worth following. Chris Corsi and his team are tackling a complicated operational challenge, one that deserves greater attention from pharmacy leaders, manufacturers, health systems, and payers. The ultimate measure of success won't be how many workflows become automated.
It will be how many more patients receive their medications, start therapy sooner, remain engaged in treatment, and avoid getting lost along the way.
That's the future of specialty pharmacy coordination worth pursuing.
References
1. Cruchelow KR, et al. (March 2026). Comparing Rates of Primary Medication Nonadherence and Turnaround Time Among Patients at a Health System Specialty Pharmacy Compared With External Specialty Pharmacies. Journal of Managed Care & Specialty Pharmacy.https://pubmed.ncbi.nlm.nih.gov/41760571/
2. Wang Y, et al. (April 17, 2026). Prior Authorization and Associated Delays and Denials of Branded Medication Dispensation. JAMA Health Forum.https://doi.org/10.1001/jamahealthforum.2026.0760
3. Doshi JA, et al. (September 30, 2026). Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients. Journal of Clinical Oncology.https://doi.org/10.1200/JCO-26-00247
4. IQVIA. (November 5, 2026). What Patient Behavior Reveals About Rural Access. U.S. Thought Leadership & Innovation.https://www.iqvia.com/locations/united-states/blogs/2026/11/what-patient-behavior-reveals-about-rural-access
5. CassianRx. (April 22, 2026). CassianRx Launches ONE Journey™ to End Fragmentation Across the Specialty Pharmacy Ecosystem. Company announcement.https://onejourneybycassian.com/insights/cassianrx-launches-one-journey-to-end-fragmentation-across-the-specialty-pharmacy-ecosystem/





